Tenofovir disoproxil fumarate (Viread®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32014000506
English
Authors' recommendations:
Tenofovir disoproxil (as fumarate) (Viread®) 245 mg film-coated tablets are recommended as an option for use within NHS Wales for the treatment of chronic hepatitis B in adults with evidence of lamivudine-resistant hepatitis B virus. Tenofovir disoproxil (as fumarate) (Viread®) 33 mg/g granules are recommended as an option for use within NHS Wales for the treatment of chronic hepatitis B in adults for whom a solid dosage form is not appropriate with evidence of lamivudine-resistant hepatitis B virus.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.awmsg.org/awmsgonline/app/appraisalinfo/2006
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- Adenine
- Organophosphonates
- Hepatitis B
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.